BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) Earnings Call Presentation

BBO-8520 (KRASG12C Inhibitor) - BBO-8520 demonstrated encouraging efficacy, safety, and early durability data in monotherapy [80] - In monotherapy, BBO-8520 achieved a 65% ORR (11/17 patients) and a 100% DCR (17/17 patients) in previously treated KRASG12C NSCLC patients [21] - 83% of patients eligible for 6-month follow-up remained on treatment for at least 6 months, with a 6-month PFS of 66% [23, 27] - BBO-8520 in combination with pembrolizumab showed early efficacy data and a distinct tolerable safety profile [80] - In combination with pembrolizumab, the TRAE rate was 47% (7/15 patients), with a Grade ≥3 TRAE rate of 13% (2/15 patients) [33] - Early efficacy signals were observed in resistant STK11/KEAP1 co-mutants [45, 80] BBO-11818 (panKRAS Inhibitor) - BBO-11818 demonstrated a partial response (PR) in a patient with pancreatic cancer [6, 56, 80] - BBO-11818 showed anti-tumor activity across dose levels and tumor types with tumor reductions at higher dose levels [7, 55, 80] - The company observed a differentiated safety profile in dose escalation [7, 80] BBO-10203 (RAS:PI3Kα Breaker) - BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on HbA1c levels [7, 80] - BBO-10203 monotherapy DCR was 62% (13/21 patients) [76]